Radoslaw Nowak

• Assessing the strengths, limitations and translational value of phenotypic screening for discovering novel proximity therapeutics
• Comparing biology-first and chemistry-first approaches, and how each guides hit identification, mechanistic validation and modality selection
• Exploring how biology-first strategies and complex disease-relevant assays can unlock non-degrader modalities such as stabilisers, modulators and activators
• Integrating AI-driven modelling and in silico cooperativity prediction with phenotypic and mechanistic workflows to accelerate molecular glue discovery

• Showcasing TRAP-1, a novel small molecule that facilitates ternary complex formation between mutant p53 and BRD4, enabling transcriptional reactivation of p53 in oncogenic contexts.
• Demonstrating robust induction of p53 target genes and selective growth inhibition in p53Y220C pancreatic cancer models, underscoring the mechanistic requirement for chemically induced proximity.
• Establishing TCIPs as a promising therapeutic modality to restore tumour suppressor function and address historically intractable transcription factor targets.

Non-Degrader